THERAPEUTIC INDICATION: EPCLUSA® is indicated for the treatment of Chronic Hepatitis C virus (HCV) infection in adults.¹
למידע נוסף על בטיחות ויעילות, אנא עיין בעלון לרופא של אפקלוזה המפורסם במאגר התרופות של משרד הבריאות.
In a large-cohort international real-world study, all patients with unknown genotype (n = 42), unknown fibrosis score (n = 82) and unknown treatment history (n = 33) were cured with EPCLUSA for 12 weeks.2 EASL defines cure as SVR, i.e. undetectable HCV RNA after treatment completion. 6
EPCLUSA offers an RBV-free STR option for the majority of HCV patients, excluding those with decompensated cirrhosis. For further information on restrictions please refer to the Prescribing Information. The addition of RBV is recommended for the treatment of patients with decompensated cirrhosis and may be considered for the treatment of HCV GT3 patients with compensated cirrhosis 1
In a Phase 2 study in patients with chronic HCV and CPT-C cirrhosis, EPCLUSA + RBV for 12 weeks led to a 78% (25/32) SVR12 rate. Treatment was well tolerated, with observed AEs consistent with expectations for a patient population with advanced liver disease. 5
EPCLUSA® Israeli prescribing information, April 2020.